Propilnorapomorfin

Propilnorapomorfin
(IUPAC) ime
	(6aS)-6-propil-5,6,6a,7-tetrahidro-4H-dibenzo[de,g]hinolin-10,11-diol
Klinički podaci
Identifikatori
CAS broj	57559-68-9
ATC kod	nije dodeljen
PubChem	5311191
ChemSpider	4470712
Hemijski podaci
Formula	C19H21NO2
Mol. masa	295,38 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H21NO2/c1-2-9-20-10-8-12-4-3-5-14-17(12)15(20)11-13-6-7-16(21)19(22)18(13)14/h3-7,15,21-22H,2,8-11H2,1H3 ; Key: BTGAJCKRXPNBFI-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Uncontrolled
Način primene	Oralno

N-n-Propilnorapomorfin (NPA) je derivat aporfina koji deluje kao dopaminski agonist. On je blisko srodan sa apomorfinom.^[4]^[5] Pokazano je da kod glodara između ostalog proizvodi hiperaktivnost, stereotipiju, hipotermiju, antinocepciju, i erekciju.^[6]^[7]^[8]^[9]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Miller RJ, Kelly PH, Neumeyer JL (January 1976). „Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain”. European Journal of Pharmacology 35 (1): 77–83. DOI:10.1016/0014-2999(76)90302-2. PMID 943290.
↑ Creese I, Padgett L, Fazzini E, Lopez F (July 1979). „3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors”. European Journal of Pharmacology 56 (4): 411–2. DOI:10.1016/0014-2999(79)90274-7. PMID 477735.
↑ Menon MK, Clark WG, Neumeyer JL (November 1978). „Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine”. European Journal of Pharmacology 52 (1): 1–9. DOI:10.1016/0014-2999(78)90015-8. PMID 569056.
↑ Riffee WH, Wilcox RE, Smith RV (March 1979). „Stereotypic and hypothermic effects of apomorphine and N-n-propylnorapomorphine in mice”. European Journal of Pharmacology 54 (3): 273–7. DOI:10.1016/0014-2999(79)90086-4. PMID 570924.
↑ Neumeyer JL, Reinhard JF, Dafeldecker WP, et al. (January 1976). „Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine”. Journal of Medicinal Chemistry 19 (1): 25–9. DOI:10.1021/jm00223a006. PMID 942751.
↑ Benassi-Benelli A, Ferrari F, Quarantotti BP (December 1979). „Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats”. Archives Internationales De Pharmacodynamie Et De Thérapie 242 (2): 241–7. PMID 44457.

Povezano

Apomorfin

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[pmid943290-4] Miller RJ, Kelly PH, Neumeyer JL (January 1976). „Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain”. European Journal of Pharmacology 35 (1): 77–83. DOI:10.1016/0014-2999(76)90302-2. PMID 943290.

[pmid477735-5] Creese I, Padgett L, Fazzini E, Lopez F (July 1979). „3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors”. European Journal of Pharmacology 56 (4): 411–2. DOI:10.1016/0014-2999(79)90274-7. PMID 477735.

[pmid569056-6] Menon MK, Clark WG, Neumeyer JL (November 1978). „Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine”. European Journal of Pharmacology 52 (1): 1–9. DOI:10.1016/0014-2999(78)90015-8. PMID 569056.

[pmid570924-7] Riffee WH, Wilcox RE, Smith RV (March 1979). „Stereotypic and hypothermic effects of apomorphine and N-n-propylnorapomorphine in mice”. European Journal of Pharmacology 54 (3): 273–7. DOI:10.1016/0014-2999(79)90086-4. PMID 570924.

[pmid942751-8] Neumeyer JL, Reinhard JF, Dafeldecker WP, et al. (January 1976). „Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine”. Journal of Medicinal Chemistry 19 (1): 25–9. DOI:10.1021/jm00223a006. PMID 942751.

[pmid44457-9] Benassi-Benelli A, Ferrari F, Quarantotti BP (December 1979). „Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats”. Archives Internationales De Pharmacodynamie Et De Thérapie 242 (2): 241–7. PMID 44457.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]